Clinical Trial Update: Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL) [Phase 2]

View source ↗

Summary

A Phase 2 RADICAL trial evaluated reduced fluence Visudyne in combination with an anti-VEGF agent and dexamethasone for choroidal neovascularization in age-rela…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization

Drugs mentioned

• Anti-VEGF agent
• DEXAMETHASONE (Dexamethasone)
• Visudyne (verteporfin)

Snippet

Sponsor: QLT Inc. | Conditions: Choroidal Neovascularization, Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2010-06-22